Overall verdict
Neutral
6.3/10
1-year performance
+20.12%
Score breakdown
Up 20.1% over 1 year, 93% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 2.6/10.
27 analysts, target +0.1% vs the price.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases.
Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments ;
immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases ; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products ;
transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market ; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nyse
United States
CEO
Marc Casper
Founded
1956
Employees
125 000
Revenue / employee
356 448 USD
Next earnings
January 20, 2027 (estimated)
Institutional holders
- FMR LLC5.98%
- GEODE CAPITAL MANAGEMENT, LLC2.28%
- Bank of New York Mellon Corp1.11%
- Rest of the register90.62%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
723.08 USD
52-week low
435.27 USD
1-year performance
20.12%
Rising
Year-to-date performance
21.11%
Rising
Drawdown
-2.94%
Near its high
Position in the 52-week range
93% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Thermo Fisher | $288,501 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-44 % between August 2008 and December 2008. $10,000 placed at the top fell to $5,626. The world ETF, at worst: -53 %. Back to its high in 29 months.
Thermo Fisher earned 4 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Thermo Fisher: $288,501
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 446.87 USD - 532.87 USD (2 methods agree)
The price implies growth of 12.03% per year; the company grows at 2.11%.
Gross margin 40.5%, net margin 14.9%, ROIC 8.0%, ROE 13.4%.
Net margin
14.94%
Exceptional
Sector 3.88%|S&P 13.40%
Gross margin
40.49%
Fair
Return on equity (ROE)
13.38%
Exceptional
Sector 3.46%|S&P 17.06%
Return on invested capital (ROIC)
8.00%
Exceptional
Free cash flow margin (FCF)
16.04%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.07x
High
Margin stability
3.0 pts
Steady
Revenue to net income
Growth
2.6/10Revenue up 9.1% over 1 year, 6.7% a year over 5, EPS 2.1% a year over 5.
Revenue (trailing 12 months)
47.4Md USD
Revenue growth (1y)
9.13%
Solid
Revenue growth (3y)
-0.80%
Declining
EPS growth (1y)
8.51%
Moderate
EPS CAGR (5y)
2.11%
Low
EPS revisions (3 months)
0.63%
Revised up
Valuation
4.3/10P/E 37.0x, forward P/E 35.9x, EV/EBITDA 24.3x, PEG 17.55. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
37.0x
Fair
Sector 50.5x|S&P 23.6x
Forward P/E
35.9x
Fair
EV / EBITDA
24.3x
Fair
Sector 22.4x|S&P 15.5x
PEG
17.55
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
508.04 USD
Overvalued
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
260Md USD
Financial strength
5.5/10Cash covers 14.7% of the debt, net debt/EBITDA 2.8x.
Net debt / EBITDA
2.8x
Stretched
Gearing (net debt / equity)
64.30%
Tight
Cash
6.1Md USD
Cash / market cap
2.33%
Stretched
Cash / total debt
14.67%
Stretched
Interest coverage
5.5x
Solid
Net debt
35.3Md USD
Equity
54.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 718.20 USD
- MM20692.89
- MM50664.82
- MM200553.91
- RSI 1460.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.57%
200-day average slope, 3 months
+4.05%
50-day average slope, 1 month
+5.84%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.04 % per day
Volatility change
+6.39%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 19.53 (9) | 25.28 (26) | 48 008 (25) | 12 564 (18) | 7 359 (6) |
| 2027 | 22.73 (10) | 27.78 (27) | 50 538 (25) | 13 534 (18) | 8 355 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 2, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.7 | 8.2 | 68.4Md USD | — | — | 70.5 % | — | -1.7x | — | 62.1 % | ||
| 2 | IQV | 7.3 | 6.9 | 45.2Md USD | 33.4x | 8.1 % | 8.0 % | 6.8 % | 4.1x | 4.6 % | 28.0 % | ||
| 3 | A207940 | 7.1 | 7.0 | 52.5Md USD | 39.7x | 41.1 % | -10.2 % | — | -0.2x | — | -24.4 % | ||
| 4 | A | 6.5 | 6.0 | 49.9Md USD | 34.8x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.5 % | 20.4 % | ||
| 5 | DHR | 6.5 | 6.4 | 166Md USD | 38.5x | 16.7 % | 8.3 % | 5.9 % | 2.0x | 3.5 % | 11.5 % | ||
| 6 | TMO | 6.3 | 5.5 | 260Md USD | 37.0x | 14.9 % | 9.1 % | 8.0 % | 2.8x | 2.9 % | 20.1 % | ||
| 7 | LONN | 5.6 | 4.7 | 54.1Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.5 % | 22.7 % | ||
| 8 | MTD | 5.3 | 4.9 | 34.8Md USD | 37.9x | 22.2 % | 6.3 % | 47.4 % | 1.8x | 2.5 % | 21.0 % | ||
| 9 | WAT | 4.3 | 1.7 | 46.3Md USD | 202.3x | 1.8 % | 120.9 % | 0.8 % | 0.8x | 0.6 % | 23.9 % |
